Anthracycline Doses in Patients with Liver Dysfunction
Author Information
Author(s): NA Dobbs, CJ Twelves
Primary Institution: Imperial Cancer Research Fund Medical Oncology Unit
Hypothesis
Do UK oncologists follow current recommendations for anthracycline dose modifications in patients with liver dysfunction?
Conclusion
UK oncologists show significant variability in prescribing anthracycline doses for patients with liver dysfunction, often differing from current recommendations.
Supporting Evidence
- Oncologists reported a wide range of anthracycline doses prescribed for patients with liver dysfunction.
- Medical oncologists were more likely to prescribe lower doses than clinical oncologists.
- 42% of oncologists would prescribe a dose at least 25% greater than the recommended dose for patients with raised bilirubin.
Takeaway
Doctors sometimes give different amounts of medicine to cancer patients with liver problems, and they don't always follow the rules about how much to give.
Methodology
A postal questionnaire was sent to UK consultant oncologists asking about their prescribing habits for anthracyclines in patients with liver dysfunction.
Potential Biases
Potential bias due to the self-selection of respondents and the nature of postal surveys.
Limitations
The study relies on self-reported data from oncologists, which may not fully represent actual prescribing practices.
Participant Demographics
UK consultant oncologists, including both clinical and medical oncologists.
Statistical Information
P-Value
0.04
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website